Novartis raised its 2024 earnings guidance for the third time on Tuesday, buoyed by wider use of its prescription drugs, but ...

CERRITOS, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Today, the Oncology Institute, Inc. and its affiliates (NASDAQ: TOI) announced that they have received certification to begin administering Pluvicto ...

Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well ...

Pluvicto (lutetium [177Lu] vipivotide tetraxetan), which won FDA approval in 2022, is fast becoming the dominant RLT for ...

Pluvicto becomes the first PSMA-targeted intravenous radioligand therapy – combining a targeting compound or ligand with a therapeutic radionuclide or radioactive particle (in this case ...

As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ramped up legal actions against its competitors. | As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ...

Pluvicto™ (formerly 177Lu-PSMA-617) is a radioligand therapy that was approved by the FDA in March 2022 to treat progressive, PSMA positive metastatic castration-resistant prostate cancer. Pluvicto™ ...

Drugmakers are trying to replicate the success Novartis has found with Pluvicto and Lutathera. Radiopharmaceuticals are ...

As expected, Novartis’ radioligand therapy Pluvicto crossed the blockbuster sales threshold with one quarter still left of 2024. But some may not be satisfied with the prostate cancer med’s ...

Novartis reports strong Q3 earnings but faces investor concerns over revenue adjustment and pipeline uncertainties. Learn more about NVS stock here.

Kisqali Sales Growth: 43% increase, with 50% growth in the US. Pluvicto Sales Growth: 50% increase, adjusted growth of 36% ...